Sai Life Sciences IPO GMP History
Sai Life Sciences IPO has been listed on December 18, 2024 at a listing price of ₹650, against the issue price of ₹549 — a gain of ₹101 (+18.4%). The GMP peaked at ₹70 on 17 December 2024 and reached a low of ₹27 on 13 December 2024. The day-wise GMP trend below shows how grey market sentiment evolved from subscription to listing.
Sai Life Sciences IPO raised ₹3042.62 Cr. through its IPO at a price band of ₹522 to ₹549 per share, with a lot size of 27 shares. The IPO was open for subscription from 11 Dec 2024 to 13 Dec 2024.
Researched & reviewed by
Abhishek Vohera,
Founder, IPO Guru
Last updated
Figures sourced from the RHP, BSE & NSE
GMP trend
Grey market premium sampled three times a day (11 AM, 5 PM, 10 PM). Last updated 10 Nov, 11:34 PM IST.
Day-wise GMP
The last reading of each day, newest first. Arrows compare with the previous day.
| Date | GMP | ↑↓ | % | Kostak | Sub. Sauda |
|---|---|---|---|---|---|
| 17 Dec 2024 | ₹ 70 | ▲ | 13% | — | — |
| 16 Dec 2024 | ₹ 42 | ▲ | 8% | — | — |
| 14 Dec 2024 | ₹ 38 | ▲ | 7% | — | — |
| 13 Dec 2024 | ₹ 27 | ▼ | 5% | — | — |
| 12 Dec 2024 | ₹ 38 | ▲ | 7% | — | — |
| 11 Dec 2024 | ₹ 33 | ▼ | 6% | — | — |
| 10 Dec 2024 | ₹ 35 | ▲ | 6% | — | — |
| 09 Dec 2024 | ₹ 30 | — | 5% | — | — |
| 07 Dec 2024 | ₹ 30 | — | 5% | — | — |
Sai Life Sciences IPO dates
Key dates from opening to listing. Today is 14 November.
- Open 11 Dec 2024
- Close 13 Dec 2024
- Allotment 16 Dec 2024
- Refund/credit 17 Dec 2024
- Listing 18 Dec 2024
Sai Life Sciences IPO actual listing price
How the grey market's final call compared with the listing-day open.
| Issue price | ₹549 |
|---|---|
| GMP-based estimate (pre-listing) | ₹619 (+12.8%) |
| Listing gain / loss | +₹101 per share |
| Listing date | 18 Dec, 2024 |
| Actual listing price | ₹650 (+18.4%) |
Is Sai Life Sciences IPO GMP reliable?
Grey market premium for Sai Life Sciences IPO should be interpreted with caution. The GMP is an unregulated, unofficial market not governed by SEBI. Here's how to read the current signal:
- 01Subscription rate matters: A high GMP paired with strong subscription — especially QIB (Qualified Institutional Buyer) oversubscription — is a more reliable bullish signal than GMP alone. Read our in-depth analysis: GMP vs Subscription Data — Which Predicts Listing Gains Better?
- 02Timing matters: GMP in the first 1–2 days of subscription is less reliable. GMP on the final subscription day and the day before listing tends to be the most accurate predictor.
- 03Grey market is thin: For smaller IPOs, even a handful of large orders can swing the GMP significantly. Treat low-volume GMP signals with extra caution.
- 04Cross-check before acting: Review the Sai Life Sciences IPO full review for a fundamentals-based assessment before making any grey market trades.
Sai Life Sciences IPO Kostak rate explained
Two ways the grey market trades an IPO application before listing.
The Kostak rate for Sai Life Sciences IPO was not available during the subscription period. Kostak is the fixed amount a grey market buyer pays for an IPO application regardless of allotment outcome.
The Subject to Sauda price was not available for this IPO. Subject to Sauda only applies if allotment is confirmed — the buyer pays a premium on top of the issue price per lot allotted.
Grey market trading is unofficial and unregulated by SEBI. Proceed with full awareness of the associated risks.
About Sai Life Sciences IPO
Sai Life Sciences Limited was incorporated on 25 January 1999. It is a pure-play, fully integrated, innovator-focused contract research, development and manufacturing organisation (CRDMO).
It provides end-to-end services across drug discovery, development and manufacturing for small molecule new chemical entities, serving global pharmaceutical innovators and biotech firms. It has both discovery and contract research and CMC and CDMO capabilities.
Its promoters include Kanumuri Ranga Raju, Krishnam Raju Kanumuri, Kanumuri Mytrey and Sai Quest Syn.
The IPO was Rs 3,042.62 crore, with Rs 950.00 crore of fresh issue and Rs 2,092.62 crore of offer for sale, mostly by TPG and HBM investors, with Sai Quest Syn also selling. Fresh money was mainly planned for repaying borrowings.
Frequently asked
What is the GMP of Sai Life Sciences IPO?
The current Grey Market Premium (GMP) of Sai Life Sciences IPO is ₹ 70.
What is the Kostak Price of Sai Life Sciences IPO?
Kostak rate is the profit made by selling an IPO application before allotment. The current Kostak rate for Sai Life Sciences IPO is not available.
What is the Subject to Sauda Price of Sai Life Sciences IPO?
Subject to Sauda is the premium amount decided if the allotment is confirmed. The current Subject to Sauda rate is not available.
What was the actual listing price of Sai Life Sciences IPO?
Sai Life Sciences IPO listed on December 18, 2024 at ₹650, against the issue price of ₹549 — a gain of +18.4%.
How did the GMP of Sai Life Sciences IPO trend before listing?
The GMP of Sai Life Sciences IPO was rising in its final days before listing. The GMP peaked at ₹70 on 17 December 2024. View the day-wise table above for the complete GMP history.
Explore Sai Life Sciences IPO further
The grey market is one signal. Read it alongside the demand, the reviews and the filings before you decide.
It has listed — go back to the fundamentals.
Category-wise demand from QIB, NII and retail investors, updated through the day.
What brokers and analysts are saying about this issue, in one place.
Check with your PAN whether shares were credited to your demat account.
The grey market called it. Now check the fundamentals.
IPO Guru tracks GMP, subscription and allotment for every Mainboard and SME issue. Read the grey market alongside the subscription book and the offer document before you apply.
Not investment advice. Grey market premium is an unofficial, unregulated indicator and is not a forecast.
